

**PROGRESSIVE'S EVENING STROLL**

**DATE: 03 February, 2026**

**Market Snapshot:**

Following a strong start, the Index pared back some of its gains and then oscillated in a narrow range for the rest of the day, eventually settling the session at 25,727.55, up by 639.15 points. All sectors ended the day in green, with the Capital Market and Realty being the best performers. Mid and Smallcaps advanced by over 2.80% and outperformed the Frontline Index.

**HOW THE DAY TRENDED**



**INDICES**

Index	Close	Points	%Chg.
Sensex	83739.13	2072.67	<b>2.54</b>
Nifty50	25727.55	639.15	<b>2.55</b>
Nifty Midcap 100	59307.10	1639.50	<b>2.84</b>
Nifty Small Cap 100	16988.95	465.60	<b>2.82</b>

**SECTORAL GAINERS / LOSERS**

Sectors	Close	Points	%Chg.
NIFTY CAPITAL MKT	4747.65	240.15	<b>5.33</b>
NIFTY REALTY	815.30	37.30	<b>4.79</b>
NIFTY ENERGY	35657.55	1044.25	<b>3.02</b>
NIFTY PHARMA	22200.25	650.70	<b>3.02</b>

**NIFTY TOP GAINERS / LOSERS**

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
ADANI ENT	2202.60	<b>10.38</b>	TECH MAHINDRA	1716.50	<b>(0.44)</b>
ADANI PORTS	1530.80	<b>9.10</b>	BEL	438.95	<b>(0.03)</b>
JIO FIN	263.90	<b>8.11</b>	NESTLE IND	1308.00	<b>(0.02)</b>
BAJAJ FINANCE	964.40	<b>6.72</b>			

**INDICES LEVELS FOR February 04, 2026**

Nifty (future)	
Resistance	26220
Support	25560

Bank Nifty (future)	
Resistance	60840
Support	59500



**PROGRESSIVE'S EVENING STROLL****DATE: 03 February, 2026****KEY TAKEAWAYS OF THE DAY**

◆ **Unichem Labs' Kolhapur facility completes USFDA Inspection with five observations, no data integrity issues:**  
The USFDA conducted an inspection at the company's Kolhapur API facility from January 27 to February 2. The inspection closed with five observations, which were largely procedural in nature, and none were related to data integrity. The company will provide the necessary responses to the USFDA within the stipulated 15-day period.

◆ **IRB Infra transfers Gandeva Ena HAM project to InvIT, cuts debt by Rs700cr:**  
The company has transferred its 100% equity share capital in VM7 Expressway (Gandeva-Ena HAM project) to the IRB InvIT Fund for Rs513cr. Following this asset transfer, the company's consolidated debt is expected to reduce by approximately Rs700cr. The proceeds would enable IRB to pursue future growth opportunities in the infrastructure space, while also supporting portfolio optimisation and long-term value creation for stakeholders.

◆ **Sun Pharma sees US generics stabilising, pins growth on innovation push:**  
Sun Pharma is looking to stabilise its US generics business as manufacturing compliance improves and new product launches resume, while sharpening its strategic focus on innovation-led growth, selective acquisitions and major near-term opportunities such as the launch of generic semaglutide in India. Sun Pharma's management said the pressure on the US generics portfolio—which has faced price erosion and competition- is expected to ease once regulatory and manufacturing constraints are resolved.

◆ **Capgemini to sell US subsidiary with ICE contract after criticism in Europe:**  
Capgemini has launched an immediate effort to sell its Capgemini Government Solutions division in the US. The business unit has come under fire for working with US Immigration and Customs Enforcement. Capgemini determined that the customary legal restrictions imposed for contracting with federal government entities carrying out classified activities in the US did not allow the group to exercise appropriate control over certain aspects of the operations of this subsidiary to ensure alignment with the group's objectives.

**Source: Media Reports**



#### DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

#### Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

#### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai—400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500.

#### Compliance Officer:

Ms. Mamatha Poojari,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500.

#### Grievance Officer:

Email: grievancecell@progressiveshares.com

